The publications on this site are part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726

Skip to Page Content

Full Deal Summary

Myriad Genetics Inc. and Pfizer Inc. are teaming up to commercialize Myriad’s BRACAnalysis CDx as a companion diagnostic with the Big Pharma’s breast cancer drug talazoparib.

Each firm will commercialize their own products but will collaborate on certain commercial activities intended to support BRACAnalysis CDx as a tool for identifying breast cancer patients that would benefit from treatment with talazoparib. BRACAnalysis CDx and talazoparib are currently being reviewed by the FDA. Myriad expects a regulatory decision by December. Talazoparib is a poly ADP ribose polymerase (PARP) inhibitor with priority review status from the FDA as a treatment for advanced breast cancer patients with germline BRCA mutations. The compound originated at BioMarin and Medivation got exclusive global rights in August 2015. One year later, Pfizer gained the compound through its $14bn acquisition of Medivation. According to BioMedTracker, talazoparib has an 85% likelihood of approval (3% above average).

Update 10/2018

One week after the deal was announced, the FDA approved BRACAnalysis CDx as a companion diagnostic with talazoparib (Talzenna).

+ Show All | – Hide All


There are no financials available.

Product Information

Click a keyword for comparable deals.

Product 1 of 2
Product Type Diagnostic
Brand Name BRACAnalysis CDx
Product Therapeutic Area(s) of Focus Cancer
Solid Tumor
Breast Cancer

Product 2 of 2
Product Type Pharmaceutical
Generic Name Talazoparib
Brand Name Talzenna
Lab Code MDV3800
Mechanism of Action Poly (ADP-ribose) polymerase (PARP) 1 inhibitor
DNA repair enzyme inhibitor
Poly (ADP-ribose) polymerase (PARP) 2 inhibitor
Highest Phase at Time of Deal Clinical Development
Filed for approval
Product Therapeutic Area(s) of Focus Cancer
Solid Tumor
Breast Cancer